Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide encoded by the 12S rRNA gene. Naturally produced in the body and declines with age. Emerging research shows remarkable effects on metabolism, insulin sensitivity, and exercise capacity.
A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets fat metabolism without the growth-promoting effects of full HGH.
Acts as a metabolic regulator that activates AMPK, promotes glucose uptake, reduces fat accumulation, and enhances mitochondrial function. Translates mitochondrial stress signals into adaptive cellular responses. Shown to extend lifespan in mouse models.
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing action of natural growth hormone without affecting blood sugar or tissue growth.
- Metabolic health optimization
- Insulin sensitivity improvement
- Obesity treatment (investigational)
- Osteoporosis prevention
- Exercise performance enhancement
- Fat loss
- Metabolic health
- Body composition improvement
- Cartilage repair (emerging research)
- Very limited human clinical data
- Optimal dosing not established
- Long-term effects unknown
- Injection site reactions
- Limited efficacy data in humans
- Injection site reactions
- Headaches
- Phase 2 trials showed modest results
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for obesity and osteoporosis indications. One of the more scientifically novel compounds on the PCAC list, with strong preclinical data but limited human trials. Compounding not yet authorized.
PCAC: July 23, 2026
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Previously reached Phase 2 clinical trials for obesity but was not pursued further by the original developer. Available through licensed 503A compounding pharmacies with a physician prescription.
- AOD9604 - a novel anti-obesity drug
2001 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.